NDAORALCAPSULE, EXTENDED RELEASE2 Generics Approved
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Data completeness
3/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDIZEM CD is an extended-release oral capsule formulation of diltiazem hydrochloride, a calcium channel antagonist indicated for hypertension. It works by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle, causing vasodilation and reduced peripheral vascular resistance. The drug produces antihypertensive effects without reflex tachycardia and is suitable for patients requiring once-daily dosing.
$3MPart D
LOE ApproachingDeclining
This product is entering loss-of-exclusivity phase with minimal Part D spending ($3M), signaling a shrinking team focused on managed care and generic transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CARDIZEM CD careers are concentrated in commercial, managed care, and medical affairs functions supporting a mature, increasingly generic-threatened hypertension brand. Opportunities exist in brand management, reimbursement strategy, and market access roles focused on maintaining share against newer mechanisms and combination therapies, but growth potential is limited.
Company
Worked on CARDIZEM CD at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.